Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
You can use this work for any purpose, as long as it is not primarily intended for or directed to commercial advantage or monetary compensation. You should also provide attribution to the original work, source and licence. Read more about this licence.
Credit
Hormone replacement therapy. Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Source: Wellcome Collection.
A discussion between John Studd from King's College Hospital Medical School and Mr. Geoffrey Chamberlain. The following summary accompanies the cassette: "Following ovarian failure there is a 13-fold increase in plasma FSH and a 3-fold increase in luteinizing hormone together with a fall in oestrone and oestradiol to 20% of their normal follicular phase values. Oestrogen therapy will remove most of the symptoms of the climacteric but there is no doubt that unopposed oestrogens carry a risk of hyperplasmia and possibly endometrial carcinoma. Hyperplasia can be prevented by giving 10 days of a progestogen with the cyclical oestrogen therapy and this should be the recommended regimen of therapy. If cystic glandular hyperplasia does occur with unopposed oestrogens it can invariably be corrected with two 21 day courses of a progestogen. Scanning electron microscopy is being used to characterise the cell surface morphology in normal hyperplastic malignant endometrial cells." 6 segments.